The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
Open accessAbstract
IL-2 immunotherapy is an attractive treatment option for certain metastatic cancers. However, administration of IL-2 to patients can lead, by ill-defined mechanisms, to toxic adverse effects including severe pulmonary edema. Here, we show that IL-2–induced pulmonary edema is caused by direct interaction of IL-2 with functional IL-2 receptors (IL-2R) on lung endothelial cells in vivo. Treatment of mice with high-dose IL-2 led to efficient expansion of effector immune cells expressing high levels of IL-2Rβγ, including CD8+T cells and natural killer cells, which resulted in a considerable antitumor response against s.c. and pulmonary B16 melanoma nodules. However, high-dose IL-2 treatment also affected immune cell lineage marker-negative CD31+pulmonary endothelial cells via binding to functional αβγ IL-2Rs, expressed at low to intermediate levels on these cells, thus causing pulmonary edema. Notably, IL-2–mediated pulmonary edema was abrogated by a blocking antibody to IL-2Rα (CD25), genetic disruption of CD25, or the use of IL-2Rβγ–directed IL-2/anti-IL-2 antibody complexes, thereby interfering with IL-2 binding to IL-2Rαβγ+pulmonary endothelial cells. Moreover, IL-2/anti-IL-2 antibody complexes led to vigorous activation of IL-2Rβγ+effector immune cells, which generated a dramatic antitumor response. Thus, IL-2/anti-IL-2 antibody complexes might improve current strategies of IL-2–based tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., & Lenardo, M. J. (2007) · Nature Immunology · doi:10.1038/ni1536 · Cited by 1,286
Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment
Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A., & Alt, F. W. (1995) · Immunity · doi:10.1016/1074-7613(95)90180-9 · Cited by 1,080
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 870
Self-citationRandomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
The IL-2 Receptor Complex: Its Structure, Function, and Target Genes
Minami, Y., Kono, T., Miyazaki, T., & Taniguchi, T. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001333 · Cited by 604
Rosenstein, M., Ettinghausen, S. E., & Rosenberg, S. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.5.1735 · Cited by 530
Webster, K. E., Walters, S., Kohler, R. E., Mrkvan, T., Boyman, O., Surh, C. D., Grey, S. T., & Sprent, J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082824 · Cited by 514
Self-citationKlapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 434
Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo
Blattman, J. N., Grayson, J. M., Wherry, E. J., Kaech, S. M., Smith, K. A., & Ahmed, R. (2003) · Nature Medicine · doi:10.1038/nm866 · Cited by 396
Cytokines and T-cell homeostasis
Boyman, O., Purton, J. F., Surh, C. D., & Sprent, J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.015 · Cited by 279
Self-citationIL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets
Létourneau, S., Krieg, C., Pantaleo, G., & Boyman, O. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.011 · Cited by 271
Self-citationTreatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
IL-2 receptor α−/− mice and the development of primary biliary cirrhosis
Wakabayashi, K., Lian, Z.-X., Moritoki, Y., Lan, R. Y., Tsuneyama, K., Chuang, Y.-H., Yang, G.-X., Ridgway, W., Ueno, Y., Ansari, A. A., et al. (2006) · Hepatology · doi:10.1002/hep.21385 · Cited by 233
Létourneau, S., van Leeuwen, E. M. M., Krieg, C., Martin, C., Pantaleo, G., Sprent, J., Surh, C. D., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909384107 · Cited by 205
Self-citationBoyman, O., Surh, C. D., & Sprent, J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1323 · Cited by 155
Self-citationB and T lymphocyte attenuator regulates CD8+ T cell–intrinsic homeostasis and memory cell generation
Krieg, C., Boyman, O., Fu, Y., & Kaye, J. (2007) · Nature Immunology · doi:10.1038/ni1418 · Cited by 148
Self-citationAn intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2
Cho, J.-H., Boyman, O., Kim, H.-O., Hahm, B., Rubinstein, M. P., Ramsey, C., Kim, D. M., Surh, C. D., & Sprent, J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070740 · Cited by 145
Self-citationShanafelt, A. B., Lin, Y., Shanafelt, M.-C., Forte, C. P., Dubois‐Stringfellow, N., Carter, C., Gibbons, J. A., Cheng, S.-L., Delaria, K. A., Fleischer, R., et al. (2000) · Nature Biotechnology · doi:10.1038/81199 · Cited by 135
Schneider, K., Oltmanns, J., & Hassauer, M. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.03.001 · Cited by 123
Wilson, M. S., Pesce, J. T., Ramalingam, T. R., Thompson, R. W., Cheever, A. W., & Wynn, T. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6942 · Cited by 111
Application of IL-2 and other cytokines in renal cancer
McDermott, D. F., & Atkins, M. B. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.4.455 · Cited by 94
Assier, É., Jullien, V., Lefort, J., Moreau, J., Santo, J. P. D., Vargaftig, B. B., Silva, J. R. L. E., & Thèze, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7661 · Cited by 88
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
Fraker, D. L., Langstein, H. N., & Norton, J. A. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.3.1015 · Cited by 83
A major histocompatibility complex class I–dependent subset of memory phenotype CD8+ cells
Boyman, O., Cho, J.-H., Tan, J. T., Surh, C. D., & Sprent, J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052495 · Cited by 59
Self-citationMargolin, K. A., Atkins, M. B., Dutcher, J. P., Ernstoff, M. S., Smith, J. W., Clark, J. I., Baar, J., Sosman, J. A., Weber, J. S., Lathia, C. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1341 · Cited by 58
Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability
Epstein, A. L., Mizokami, M. M., Li, J., Hu, P., & Khawli, L. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.10.741 · Cited by 46
Edwards, M. J., Heniford, B. T., Klar, E., et al. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115904 · Cited by 41
Tsunobuchi, H., Nishimura, H., Goshima, F., Daikoku, T., Nishiyama, Y., & Yoshikai, Y. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4552 · Cited by 27
Interleukin-2 Induced Systemic Toxicity: Induction of Mediators and Immunopharmacologic Intervention
Butler, L. D., Mohler, K. M., Layman, N. K., Cain, R. L., Riedl, P. E., Puckett, L. D., & Bendele, A. M. (1989) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923978909005379 · Cited by 17
The role of nitric oxide in interleukin-2 therapy induced hypotension
Shahidi, H., & Kilbourn, R. G. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1005964907344 · Cited by 7
Cited by
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Self-citationA review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Domingues, B., Lopes, J., Soares, P., & Populo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 701
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
Metadata
- Authors
- Krieg, C., Létourneau, S., Pantaleo, G., & Boyman, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-06-14
- Volume
- 107
- Issue
- 26
- Pages
- 11906-11911
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2073128146
- Cited by
- 380
- References
- 33
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.